CREPT facilitates colorectal cancer growth through inducing Wnt/β-catenin pathway by enhancing p300-mediated β-catenin acetylation

Yanquan Zhang1,2 · Shiyan Wang1,3 · Wei Kang4 · Chunxiao Liu2 · Yujuan Dong1,5 · Fangli Ren2 · Yinyin Wang2 · Jinglin Zhang4 · Guoping Wang1 · Ka Fai To4 · Xueji Zhang3 · Joseph JY Sung1 · Zhijie Chang2 · Jun Yu1

Received: 25 June 2017 / Revised: 31 December 2017 / Accepted: 12 January 2018 / Published online: 22 March 2018
© The Author(s) 2018. This article is published with open access

Abstract
Using whole genome sequencing, we identified gene amplification of CREPT in colorectal cancer (CRC). In this study, we aim to clarify its clinical significance, biological effects, and mechanism in CRC. CREPT was upregulated in CRC cell lines and in 47.37% (72/152) of primary CRC tumors. Amplification of CREPT was detected in 48.28% (56/116) of primary CRC tumors, which was positively correlated with its overexpression (P < 0.001). Multivariate analysis showed that CRC patients with CREPT protein overexpression were significantly associated with poor disease-free survival (P < 0.05). CREPT significantly accelerated CRC cell proliferation and metastasis both in vitro and in vivo. RNA-seq analysis uncovered that the tumor-promoting effect by CREPT was attributed to enhancing Wnt/β-catenin signaling. Using co-immunoprecipitation coupled with mass spectroscopy, we identified p300 protein was a novel CREPT interacting partner. CREPT greatly increased the interaction between p300 and β-catenin, thus promoting p300-mediated β-catenin acetylation and stabilization. Moreover, CREPT cooperated with p300, leading to elevated active histone acetylation markers H3K27ac and H4Ac and decreased repressive histone marker H3K9me3 at the promoters of Wnt downstream targets. In summary, CREPT plays a pivotal oncogenic role in colorectal carcinogenesis through promoting Wnt/β-catenin pathway via cooperating with p300. CREPT may serve as a prognostic biomarker of patients with CRC.

Introduction
Colorectal cancer (CRC) is the third most common diagnosed cancer in men and the second in women worldwide [1]. More than 1 million individuals are diagnosed with CRC annually, with around 700,000 deaths occurring [2]. CRC is a multistep process with the accumulation of genetic and epigenetic alterations [3, 4]. Previous studies showed that somatic copy number alterations (CNAs) is crucial for the development of CRC [5]. Increased frequency of 7pq, 8q, 13q, and 20q gains, and of 4pq, 5q, 8p, 15q, 17p, and 18q losses were observed in colorectal adenoma and carcinoma progression [6–9]. Therefore, it is important to identify novel genes with CNAs and their biological functions in colorectal tumorigenesis.

Cell-cycle related and expression-elevated protein (CREPT) was firstly identified by our group as a potential oncogene [10]. The expression of CREPT was deregulated in many types of tumors [11–15]. CREPT is localized at human chromosome 20q11.23, which is a highly amplified region in CRC [16, 17]. CREPT functions as a scaffolds of C-terminal domain of human RNA polymerase II (RNAPII)
and cooperates with RPAP2 to dephosphorylate of phos-
pho-Ser5, thereby promoting gene transcription [18, 19].
We found that CREPT interacted and coordinated with
RNAPII and β-catenin proteins, promoting oncogenic Wnt/
β-catenin signaling and tumorigenesis [10, 20]. However,
the role and the molecular mechanism of CREPT in CRC
are still unclear. In this study, we investigated the
expression regulation, clinical application, biological function, and molecular basis of CREPT in CRC.

Results

CREPT is upregulated in colon cancer cell lines and in primary CRC tissues

We first evaluated the expression of CREPT in CRC cell lines and human tissue samples. CREPT mRNA and protein expression was dramatically enhanced in all nine CRC cell lines compared with normal human colon tissue samples and two normal human colonic epithelial cells HCEC 1CT and 2CT [21] by real-time PCR and western blot (Fig. 1a, S Fig. 1a). Keeping with the findings, CREPT protein was significantly upregulated in 13 primary CRC tissues compared with their adjacent normal tissues by western blot (P = 0.002) (Fig. 1b). To further confirm our findings, the mRNA expression of CREPT in CRC samples from TCGA database (https://genome-cancer.ucsc.edu) was analyzed. CREPT was significantly increased in 32 CRC tissues compared with paired adjacent normal tissues (P < 0.0001) (Fig. 1c). The upregulation was also observed in unpaired CRC (n = 364) compared with normal samples (n = 50) from TCGA cohort (P < 0.0001) (Fig. 1d). Taken together, CREPT is significantly upregulated in CRC, indicating that it might play an oncogenic role in CRC.

CREPT is an independent predictor of cancer recurrence in CRC patients

To evaluate the association of CREPT with the clinicopathological features and clinical outcomes of patients with CRC, we evaluated the CREPT protein expression in a tissue microarray of 152 CRC tumors. We found that 47.37% (72/152) of CRC tumors showed strong nuclear staining of CREPT, 29.61% (45/152) were moderate and 17.76% (27/152) were weak staining, and 5.26% (8/152) cases showed negative staining (Fig. 1e). CREPT was significantly upregulated in 152 tumor tissues compared with 14 normal colon tissues (P < 0.0001) (Fig. 1f). There was no significant correlation between CREPT expression and age, gender, tumor localization, differentiation, and the TNM stage of CRC patients (S Table 1). Kaplan–Meier analysis showed that CREPT high expression was significantly associated with poor disease-free survival in patients with CRC (P < 0.05, log-rank test) (Fig. 1g1, S Fig. 1b). Upregulated CREPT expression indicated a shorter disease-free survival of patients at early stage (TNM stages I and II, Fig. 1g2), but not at advanced stage (TNM stages III and IV, S Fig. 1b). In univariate Cox regression analysis,

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
| Gender    | RR (95% CI)         | P value   | RR (95% CI) | P value |
| Female    | 1                   |           | 1           |
| Male      | 0.878 (0.549-1.403) | 0.587     |             |
| Age       |                      |           |             |
| ≤60       | 1                   |           | 1           |
| >60       | 1.074 (0.678-1.702) | 0.761     |             |
| Primary tumor location |            |           |             |
| Colon     | 1.000 (1.000-1.000) | 1         |             |
| Rectum    | 0.764 (0.509-1.145) | 0.193     |             |
| Differentiation |              |           |             |
| Well      | 1                   |           | 1           |
| Poor      | 2.801 (0.387-20.310)| 0.308     |             |
| TNM       |                      |           |             |
| I         | 1                   |           | 1           |
| II        | 2.054 (0.715-6.901) | 0.181     | 2.109 (0.734-6.056)| 0.166 |
| III       | 3.454 (1.203-9.922) | 0.021     | 3.382 (1.179-9.704)| 0.023 |
| IV        | 11.460 (3.659-35.889)| <0.001   | 12.320 (3.931-38.614)| <0.001 |
| CREPT     |                      |           |             |
| Low       | 1.796 (1.002-3.219) | 0.049     | 1.897 (1.053-3.418)| 0.033 |
| High      | 1.000 (1.000-1.000) |           | 1           |

The TNM Staging System is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M).

The bold entries highlight the P value which is less than 0.05 and significant.
CREPT high expression was associated with an increased risk of cancer recurrence (RR = 1.897, 95% CI, 1.053 – 3.418; P < 0.05) (Table 1). After adjustment for potential confounding factors, multivariate Cox regression analysis showed that CREPT high expression was an independent predictor of cancer recurrence in patients with CRC (RR = 1.897, 95% CI, 1.053 – 3.418; P < 0.05) (Table 1).

Copy number gain of CREPT contributes to its upregulation in CRC

Human CREPT gene localizes at the region q11.23 of chromosome 20, which is a highly amplified region in CRC [16, 17]. By whole genome sequencing analyses of the paired CRC tissues from our group, we identified CREPT amplification in CRC [17]. To further confirm our identification, we evaluated the copy number variation from TCGA (http://www.cbioportal.org/) and found the region that CREPT localizes was markedly amplified in both rectum cancer and colon cancer (Fig. 2a). We next examined the DNA copy number variation of CREPT in a cohort of 116 primary CRC tumor tissues using a specific Taqman probe targeting CREPT. CREPT copy number gain or amplification (defined as more than two copies) was found in 48.28% (56/116) CRC cases (Fig. 2b). Furthermore, a significantly positive correlation between CREPT mRNA level and its DNA copy number gain/amplification was observed using linear regression analysis (R = 0.485, P < 0.0001) (Fig. 2c). Therefore, these results suggested that copy number gain of CREPT gene was amplified in CRC. a Significant genomic alterations of chromosome 20p13-q13 across 12 while blue color refers to copy number loss. Red box indicates the location of CREPT gene. BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, KIRC kidney renal clear cell carcinoma, COAD colorectal adenocarcinoma, GBM glioblastoma multiformed, HNSC head and neck squamous cell carcinoma, LAML acute myeloid leukemia, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, READ rectum adenocarcinoma, OV ovarian serous cystadenocarcinoma, UCEC uterine corpus endometrioid carcinoma. b DNA copy number variation of CREPT was found in 48.28% (56/116) CRC cases by real-time PCR with a Taqman probe targeting CREPT. c The correlation between copy number changes of CREPT and mRNA overexpression (R = 0.485, P < 0.0001)
Oncogenic role of CREPT in colorectal cancer

**A** Myc-CREPT

**B** sh-CREPT

**C** DLD-1

**D** EV, CREPT

**E** HT29

**F** sh-NC, sh-CREPT

**G** HGE C 1CT

**H** HGE C 2CT

**I** Tumor growth curve

**J** Tumor growth curve

**S** PRINGER NATURE
CREPT promotes CRC cell proliferation and tumorigenesis

To elucidate the function of CREPT in CRC, we examined the effects of CREPT on growth characteristics of colon cancer cells by MTT assay and colony formation assay. CREPT was overexpressed in DLD-1 and HCT116 cell lines that showed low CREPT expression and knockdown in HT29 and SW480 that showed high CREPT expression (S Fig. 1a). The efficiency of overexpression (Fig. 3a) and knockdown (Fig. 3b) of CREPT were verified by RT-PCR and western blot. Ectopic expression of CREPT significantly accelerated cell growth (Fig. 3c) and increased clonogenicity (Fig. 3d) in DLD-1 and HCT116 cells compared with empty vector transfected control cells. In contrast, knockdown of CREPT attenuated cell growth (Fig. 3e) and inhibited clonogenicity (Fig. 3f) in HT29 and SW480 cells. Furthermore, CREPT overexpression significantly accelerated the growth of two normal human colonic epithelial cells HCEC 1CT and 2CT (Fig. 3g). Soft agar assay revealed that overexpression of CREPT in transfected HCT116 cells dramatically enhanced their colony-formation ability (Fig. 3h, S Figure 2). To further assess the function of CREPT on tumorigenesis in vivo, we performed a xenograft model assay through subcutaneously injecting CREPT-overexpressing and control HCT116 cells or SW480 cells with CREPT knockdown and control cells, respectively. As shown in Fig. 3i1, the growth of tumor volume by CREPT-overexpressing cells was significantly increased compared with control cells (P < 0.01). The net weight of tumors formed by CREPT-overexpressing cells was also significantly increased compared with controls at termination of the experiment (P < 0.01; Fig. 3i2). Immunohistochemistry showed that protein expression of CREPT was greatly enhanced in xenograft tumors of the CREPT-overexpressing group compared with control group (Fig. 3i3). The tumor-promoting effect of CREPT in vivo was further confirmed in the knockdown assay of CREPT in nude mice (Fig. 3j).

CREPT enhances invasion and migration abilities of CRC cells

We also investigated the effect of CREPT on metastasis in trans-well migration and invasion assays. Ectopic expression of CREPT significantly increased cell migration (Fig. 4a) and invasion in HCT116 cells (Fig. 4b) compared with control. In contrast, knockdown of CREPT by shRNA dramatically reduced the migratory (Fig. 4c) and invasive abilities (Fig. 4d) of SW480 cells. To further valuate the ability of CREPT on metastasis in vivo, we intravenously injected HCT116 cells with overexpression of CREPT or empty vector in nude mice. After 6 weeks of injection, mice were killed and the lungs were collected. The number of metastasis nodules in lungs was significantly increased in mice injected with CREPT overexpression cells than in mice injected with control cells (P < 0.05) (Fig. 4e). Therefore, CREPT had an important role in colon cancer metastasis.

CREPT promotes Wnt/β-catenin signaling pathway in CRC

To probe the pathways regulated by CREPT in CRC, we performed RNA-seq on HCT116 cells stably transfected with CREPT or control vector. KEGG Pathway Enrichment Analysis revealed alterations in several pathways, especially WNT signaling pathway (P < 0.01, Fig. 5a, detailed gene list in S Table 2). Notably, a considerable number of differential genes were well-established WNT/β-catenin downstream targets, including CCND1, c-MYC, and AXIN2. Wnt-response luciferase reporter assay further confirmed this finding (Fig. 5b). Ectopic expression of CREPT significantly enhanced the activity of Wnt signaling reporter Top-Flash by 2.67-fold (Fig. 5b1), while knockdown of CREPT attenuated the activity of Top-flash by 50% (P < 0.01) (Fig. 5b2). We also validated the expression of these three key Wnt signaling downstream targets by RT-PCR and western blot in CREPT overexpressing and knockdown cells. The mRNA and protein expression of CCND1, c-MYC, and AXIN2 were evidently enhanced in CREPT-overexpressing DLD-1, HCT116, HCEC 1CT and 2CT cells compared to the control cells (Fig. 5c, e1, 2); while knockdown CREPT in HT-29 and SW480 cells showed reduced expression (Fig. 5d, e3).
Our group previously performed an immunoprecipitation/mass spectrometry experiment in HEK293T cells overexpressing CREPT and identified RNAPII as an interacting protein of CREPT to stimulate CCND1 expression and promote oncogenesis [10]. Using this method, p300 was also identified as a potential CREPT interacting partner (Supplementary Fig. 3a). The interaction of CREPT with p300 was further confirmed by transient transfection of Myc-tagged CREPT and HA-tagged p300 followed by co-immunoprecipitation with an anti-HA antibody (Fig. 6a). Furthermore, co-immunoprecipitation using endogenous anti-p300 antibody showed that CREPT had a strong binding to endogenous p300 in SW480 cells (Fig. 6b). To elucidate the role of p300 in CREPT-mediated tumorigenesis, we silenced p300 in CREPT-overexpressed cells (Fig. 6c) and examined the effect on cell growth and colony-formation ability. As shown in Fig. 6d, e, CREPT significantly promoted DLD-1 cell growth, whereas it was significantly dampened after p300 knockdown, suggesting that p300 was an important mediator in CREPT-promoted tumorigenesis. Increasing evidence showed that β-catenin recruits co-activator p300 to form a transcriptionally active complex [22–25]. The binding of p300 has an important effect on Wnt/β-catenin signaling, leading to differential regulation of target gene expression and different functional outcomes [26, 27]. As a critical partner of CREPT, p300 might be an important co-regulator of CREPT-mediated Wnt/β-catenin signaling activation. To test this hypothesis, we performed a luciferase reporter assay to evaluate the transcriptional activity of β-catenin/TCF4 complex under different transfection conditions. CREPT overexpression significantly increased the activity of Top-flash, whereas co-transfection of CREPT and p300 further enhanced the transcriptional activity of β-
catenin/TCF4 complex (Fig. 6f). Furthermore, co-immunoprecipitation assay results showed that β-catenin increased its affinity for TCF4 when cells were transfected with CREPT alone or p300 alone (Fig. 6g, lanes 3 and 4). Furthermore, the interaction between β-catenin and TCF4 was stronger when cells were co-transfected with CREPT.
and p300 (Fig. 6g, lane 5). Moreover, CREPT-mediated Wnt/β-catenin signaling activation was significantly inhibited after p300 knockdown (Fig. 6h, i), further confirming that CREPT cooperated with p300 in promoting Wnt/β-catenin signaling activation.

CREPT enhances the interaction between p300 and β-catenin and promotes p300-mediated acetylation and stability of β-catenin

To further explore the mechanism how CREPT cooperates with p300 to stimulate Wnt signaling, we examined the effect of CREPT on the formation of β-catenin and p300 transcriptional complex by immunoprecipitation assay. As shown in Fig. 7a, a clear increased associated β-catenin was observed in p300 precipitates from CREPT-overexpressing cells, whereas depletion of CREPT attenuated the interaction between p300 and β-catenin (Fig. 7b), indicating that the interaction between p300 and β-catenin was enhanced in the presence of CREPT. p300 is capable of functioning as acetyltransferase for nonhistone targets [28–31]. p300/CPB coactivator family-mediated acetylation of β-catenin increased its stability and the interaction between β-catenin and TCF4, contributing to β-catenin-mediated neoplastic transformation [22–24, 32–34]. Thus, we proposed that CREPT might regulate β-catenin acetylation by recruiting p300. Our results showed that β-catenin acetylation was significantly enhanced in CREPT-overexpressing cells (Fig. 7c), but decreased in CREPT knockdown cells (Fig. 7d). Especially, acetylation of endogenous β-catenin was increased in DLD-1 cells with CREPT overexpression (Fig. 7e), whereas decreased in SW480 CREPT knockdown cells (Fig. 7f). To further confirm whether CREPT affects β-catenin stability, we examined the degradation rate of β-catenin after cycloheximide treatment. The results showed that the protein level of β-catenin was significantly higher in the presence of CREPT (Fig. 7g). Therefore, our findings suggested that CREPT-mediated Wnt/β-catenin signaling activation is through cooperating with p300 and promoting β-catenin acetylation and stability.

CREPT enhances active epigenetic modification of histone in the promoter of Wnt downstream targets

p300 belongs to histone acetyltransferase and regulates transcription via histone acetylation and chromatin remodeling, thus giving an epigenetic tag for transcriptional activation [35, 36]. In this regard, the level of active histone acetylation marker H3K27ac and H4Ac and repressive histone marker H3K9me3 was examined in the promoter of Wnt target gene c-MYC, under CREPT overexpression and knockdown by quantitative ChIP-PCR. Our result showed that CREPT enhanced the level of H3K27ac and H4Ac (Fig. 7h) and reduced level of H3K9me3 in the c-MYC promoter region (Fig. 7i), indicating that p300 recruited by CREPT on Wnt/β-catenin downstream target genes and control the transcription efficiency through directly regulated histone modifications.

CREPT is positively correlated with Wnt signaling pathway in CRC patients

To further prove the clinical relevance of CREPT in CRC patients, we checked the protein expression of CREPT, β-catenin, and C-MYC in our cohort of CRC patients by IHC staining. Pearson correlation analysis revealed that the expression of CREPT significantly correlated with the expression of β-catenin, and C-MYC in CRC clinical samples (P < 0.001, Fig. 8a). Next, we performed Gene Set Enrichment Analysis (GSEA) analysis in CRC patients from TCGA based on RNA-seq data, revealing that CREPT mRNA expression was significantly positively correlated with WNT signaling and three WNT signaling-related pathways of cell cycle, MYC, and VEGF (Fig. 8b). Moreover, we verified mRNA expression levels of key WNT signaling target genes in CRC (refer to Wnt homepage: https://web.stanford.edu/group/nusselab/cgi-bin/wnt/) from TCGA CRC RNA-seq data (Fig. 8c1). We found that CCND1, C-MYC, AXIN2, CLDN1, MET, FGF18, VEGFA, and MSL1 were significantly positively correlated with CREPT mRNA expression (Fig. 8c2). These results indicated that CREPT promotes WNT signaling in CRC patients.

Discussion

In this study, we found CREPT expression was frequently upregulated in colon cancer cell lines and primary CRC tissues. High level of CREPT was associated with poor
disease-free survival for patients with CRC. Copy number gain of CREPT is one of the main regulatory mechanisms of CREPT upregulation in CRC. CREPT was located on chromosome 20q11.23, which is one of the most frequently amplified regions in CRC [16, 17]. Gene amplification is thought to promote overexpression of genes favoring tumor development [6–9]. CREPT copy number gain or amplification was observed in 48.28% (56/116) CRC cases, indicating that amplification of CREPT is a common event in colorectal tumorigenesis. Importantly, we revealed that copy number gain of CREPT was positively associated with its mRNA overexpression in 116 CRC cases ($P < 0.0001$), suggesting that increased CREPT copy number contributes.
Endogenous CREPT was capable of interacting with endogenous p300 to immunoprecipitate HA-tagged p300 from whole cell extracts prepared from HEK293T cells co-expressing Myc-CREPT and HA-p300. Endogenous CREPT was capable of interacting with endogenous p300 in SW480 cells. p300 knocking down efficiency was examined by real-time PCR and semi-quantitative PCR in DLD1 cells. DLD1 cell growth rate in p300 knockdown was slower after CREPT overexpression. Colony-formation assay indicated p300 knockdown cells showed decreased colony formation after CREPT overexpression. Anti-HA antibody was used to immunoprecipitate HA-tagged p300 from whole cell extracts prepared from DLD1 cells. p300 knockdown showed decreased clonogenicity after CREPT overexpression in DLD1 cells.

We previously demonstrated that CREPT was associated with transcriptional complexes, CREPT also coordinated with β-catenin and p300 to control Wnt pathway and its target genes including CCND1, c-MYC, and AXIN2. CREPT and p300 synergized to stimulate Wnt signaling and promote tumor cell proliferation and metastasis in colon cancer cells both in vivo and in vitro. As evidenced by p300 knockdown assay in CREPT-overexpressing cells, CREPT-mediated oncogenic functions and Wnt signaling activation were alleviated by p300 knockdown, suggesting that p300 acted as an essential co-partner of CREPT. More and more evidence demonstrated that p300 and p300/CBP coactivator family members play critical roles in regulating Wnt/β-catenin pathway through directly binding to β-catenin [22–24, 32–34]. As acetyltransferases, p300 and p300/CBP coactivator family members catalyze the acetylation of β-catenin, thereby improving β-catenin stability, increasing the affinity of β-catenin for TCF4 and leading to efficient transcription [24, 33, 34]. The acetylation of Lys345 on β-catenin by p300 increased the affinity of β-catenin for TCF4 [24]. The cooperation between p300 and β-catenin was greatly dampened by the K345R mutation, implying that acetylation of β-catenin plays an important role in efficient activation of WNT/β-catenin transcription. Interestingly, acetylation of Lys345 on β-catenin was strongly enriched in the colon cancer cells with hyperactivating Wnt/β-catenin signaling [24]. p300 was required for β-catenin-mediated neoplastic transformation in colon cancer [23]. In our study, immunoprecipitation result showed that CREPT promoted the association of β-catenin with p300 and enhanced β-catenin acetylation. The transcriptional activity of β-catenin/TCF4 complex and the binding affinity of β-catenin for TCF4 were increased to the higher degree after cotransfection of CREPT and p300. Moreover, the degradation rate of β-catenin was slowed down in the presence of CREPT after cycloheximide treatment, implying that CREPT affected the level of β-catenin via a post-translational mode due to enhanced β-catenin acetylation. Therefore, one of the key mechanisms by CREPT is that it coordinates with p300 to enhance the interaction between p300 and β-catenin, causing acetylation of β-catenin and robust activation of Wnt/β-catenin pathway. Moreover, p300 is also a histone acetyltransferase. It acted not only on β-catenin but also on chromatin directly. We found that CREPT modulated the level of active histone acetylation marker H3K27ac and H4Ac and repressive histone marker...
H3K9me3 in the promoter of Wnt target genes. Collectively, this study revealed the mechanisms underlying CREPT in regulating Wnt signaling pathway: CREPT recruited p300 to enhance the acetylation and stability of β-catenin and thus activating Wnt signaling pathway.

In summary, we have identified a novel functional oncogene CREPT overexpressed in CRC. Upregulated CREPT was associated with poor disease-free outcome. Copy number gain of CREPT contributes to its upregulation in CRC. CREPT promoted CRC growth and invasion/migration ability through coordinating with a novel interacting partner p300. CREPT and p300 synergized to stimulate Wnt/β-catenin signaling and promoted tumorigenesis in two ways (Fig. 7). On one hand, CREPT enhanced the interaction between p300 and β-catenin and promoted p300-mediated acetylation of β-catenin, leading to increased β-catenin-TCF4 complex formation on Wnt target genes. On the other hand, p300 recruited by CREPT directly regulated the histone modifications on the promoter of Wnt target genes. Collectively, CREPT plays a pivotal oncogenic role in colorectal carcinogenesis through promoting Wnt/β-catenin pathway via cooperating with p300. CREPT may serve as a prognosis biomarker for CRC patients.
Materials and methods

Plasmids and reagents

Myc-CREPT, Flag-β-catenin, HA-p300, HA-TCF4, Top-Flash, Fop-Flash constructs were used in this study. Anti-cyclinD1 (A-12), anti-Myc (9E10), anti-HA (F-7), anti-β-catenin (E-5), anti-Ac-lysine (7F8), and anti-GFP (FL) antibodies and protein G-agarose beads (sc-2002) were from Santa Cruz Biotechnology, Inc (Dallas, Texas, USA). Anti-c-Myc (9402), anti-AXIN2 (2151) used for western blot was purchased from Cell Signaling Technology, Inc (Danvers, MA). Anti-Flag (F1804), anti-β-Actin (AC-15), Crystal Violet (C3886), DMSO (D2650), and MTT (M5655) were purchased from Sigma-Aldrich (St Louis, MO). Anti-c-MYC (ab32072) for IHC, anti-H3K27ac (ab4729), anti-H3K9me3 (ab8898) antibodies were purchased from Abcam (Cambridge, MA, USA). Anti-H4ac (06-866) antibody was from Millipore (Hong Kong, China). Anti-β-catenin (M33539) for IHC was from Dako/Agilent Technologies (USA). Anti-CREPT antibody was generated by our lab. siRNAs were synthesized by Shanghai GenePharma Co. Ltd, China. The oligo sequence information as: si-p300 #1: GGACUACCCUAUCAAGUAATT; si-p300 #2: CAUCACGGGUAUACAAAUATT; si-CREPT: GCAAGAACGAAGUGUUAUTT; siRNA negative control (NC): UCUCCGAAGUCACGUTT. siRNAs were transfected into cells using Lipofectamine™ RNAiMAX.
Transfection Reagent (13778150) twice. FastStart Universal SYBR Green Master used for real-time PCR was purchased from Roche Applied Sciences (Indianapolis, IN, USA). Puromycin (A1113803) and Hygromycin B (10687010) was from ThermoFisher Scientific (Waltham, MA). Cycloheximide (CHX) was from AMRESCO Inc. (Ameresco, Ohio).

**Cell lines**

Human CRC cell lines (CaCO2, Colo205, DLD-1, HCT116, HT29, LoVo, SW1116, SW480, and SW620) and one immortalized colorectal epithelial cell line (NCM460) were from the American Type Culture Collection (Manassas, VA) and were cultured as described in previous study [37]. HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS. Cells were kept at 37 °C in a 5% CO2-containing atmosphere. Human colonic epithelial cells (HCEC) 1CT and 2CT were a gift from Prof. Jerry W. Shay (University of Texas Southwestern Medical Center, Dallas, Texas, USA) and were cultured in the conditions previously reported [21]. For generating CREPT stable overexpression or knockdown cell lines, cells were infected with lentivirus and then selected by puromycin at different concentration: 2 μg/ml (DLD-1), 1.5 μg/ml (HCT116), 2 μg/ml (HT29), 4 μg/ml (SW480) or by Hygromycin B (400 μg/ml) for HCEC 1CT and 2CT.

**Clinical samples**

Thirteen primary paired CRC samples (tumor sample and adjacent non-tumor sample) randomly selected from Prince of Wales Hospital (Hong Kong) were used for western blot detection. A tissue microarray including 152 cases of CRC patient samples from Prince of Wales Hospital was used for immunohistochemistry staining. In total, 116 CRC tissues obtained from the Beijing University Cancer Hospital (China) were used for copy number variant assay [38]. All patients signed informed consent before specimen collection. The Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee and Human Ethics Committee of Beijing University Cancer Hospital approved the ethics individually.

**Animal assay**

For xenograft model, 5×10^6 cells were subcutaneously injected into the right or left dorsal flank of each 4-week-old male Balb/c nude mice, respectively. Each experimental group consisted of five mice. Tumor volume was measured every 2 days for 4 weeks and calculated using the formula \( V = (W^2 \times L)/2 \) (\( V \) = volume, \( L \) = length, \( W \) = width). For the metastasis model, 2×10^6 cells were intravenously injected through the tail vein of nude mouse (4-week old, 5 mice/group). All mice were killed at 6 weeks after injection. The lungs from each mouse were embedded in paraffin for hematoxylin and eosin staining. All experimental procedures were approved by the Animal Ethics Committee of the Chinese University of Hong Kong.

**Copy number assay**

Gene copy number variation was performed using a TaqMan copy number assay (ThermoFisher Scientific) according to the manufacturer’s instructions. Briefly, genomic DNA was extracted from CRC samples as templates of PCR. DNA copy number was examined by real-time PCR using a specific Taqman probe against CREPT (Hs01601842_cn) and a reference probe targeted to RNase P (#4403326). Each sample was detected with four replicates to generate the reliable copy number calls. The result was analyzed using Applied Biosystems® CopyCaller® Software (http://www.appliedbiosystems.com/absite/us/en/home/support/software/real-time-pcr/copycaller.html).

**Cell proliferation analysis**

MTT assay was used for cell proliferation detection. 2000 cells/well were seeded into a 96-well plate. The absorbance at 570 nm was measured using Multiskan™ GO Microplate Spectrophotometer (ThermoFisher Scientific). Three independent experiments were performed.

**Colony formation**

For anchorage-dependent growth, 1000 cells were seeded into a six-well plate. For anchorage-independent growth in soft agar, 7000 cells were inoculated in cell culture medium containing 0.35% agar and seeded in six-well plate with medium containing 0.7% agar. Cells were grown for 2 weeks (anchorage-dependent) or 4 weeks (anchorage-independent). Cell clones were counted and presented as mean ± standard deviation (SD) from three individual experiments.

**Cell migration and invasion assay**

BD Falcon Cell Culture Inserts (#353097) purchased from BD (Franklin Lakes, New Jersey, USA) were used for migration assay. For invasion assay, BD BioCoat™ Matrigel™ Invasion Chamber (BD, #354480) was used according to the manufacturer’s instructions. The number of invaded cells was counted under a phase contrast microscope. Cells in five different fields of each well were averaged.
RNA sequencing

HCT116 cells overexpressing CREPT or empty vector were harvested for total RNA extraction. RNA sequencing and analysis were performed by Beijing Novogene Technology Co. Ltd.

Protein half-lives assay

To detect the half-life of the β-catenin protein, Flag-β-catenin was transfected into HEK293T cells alone or with Myc-CREPT. After 24 h of transfection, cells were treated with 50 μg/ml cyclohexanone (CHX) and further cultured for indicated time course. Cells lysates were examined using western blotting.

Co-immunoprecipitation and western blotting

Co-immunoprecipitation was performed as previously described [39]. Specifically, for transient transfection interaction assays, Flag-β-catenin, HA-TCF4, HA-p300 and Myc-CREPT plasmids were transfected into HEK293T cells according to the assay design. For endogenous interaction assays, the nuclear fraction of SW480 cells was used for immunoprecipitation.

Luciferase assay

HEK293T, DLD-1, or SW480 cells were transiently transfected with the indicated plasmids using Lipofectamine 2000. Luciferase activity was measured after 24 h of transfection using a Dual-Luciferase reporter assay system (E1910, Promega, Madison, WI). The luciferase activity was normalized by firefly against Renilla luciferase activity and presented as mean ± SD.

Chromatin immunoprecipitation (ChIP) assay

ChIP assay was performed as previously described [20]. Briefly, sonicated DNA was immunoprecipitated with histone modification markers H3K27Ac, H4Ac, and H3K9me3 antibodies. Normal IgG was used as negative control. ChIPed DNA was examined by real-time PCR to evaluate antibodies. Normal IgG was used as negative control.

Statistical analysis

All experiments were repeated at least three times. Data were presented as mean ± standard deviation. Correlation analysis of copy number and mRNA was performed using linear regression. Significant differences between groups were determined using the Student’s t-test. The difference between the two groups in cell growth curve and tumor growth rate of nude mice were determined by repeated-measures analysis of variance. The H-score of CREPT as a weighted sum of the intensity of IHC tumor cell nuclei was calculated as reported [41]. Survival analysis was calculated using Kaplan–Meier analysis.

Acknowledgements This project was supported by the National Natural Science Foundation (81301775, 81230044, 81572728), RGC-GRF Hong Kong (14106415, 14111216, 14163817), 135 program project (2016YFC1303200), National Key Research and Development Program (2016YFA0500301); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and do not use the material in a way that suggests endorsement or sponsorship by the author(s) or the license holder.

Statistical measures analysis of variance. The H-score of CREPT as a weighted sum of the intensity of IHC tumor cell nuclei was calculated as reported [41]. Survival analysis was calculated using Kaplan–Meier analysis.

References

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet. 2010;375:1030–47.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
3. Wood LD, Parsons DW, Jones S, Lin J, Szabo T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.
4. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.
5. Xie T, G DA, Lamb JR, Martin E, Wang K, Tejpar S, et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS ONE. 2012;7:e42001.
6. Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K, et al. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer. 1996;15:234–45.
7. Meijer GA, Hermans MA, Baak JP, van Diest PJ, Meuwissen SG, Bellien JA, et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol. 1998;51:901–9.
8. Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W, et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res. 2004;64:4817–25.

9. Nakao K, Mehta KR, Fridlyand J, Moore DH, Jain AN, Lafuente A, et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis. 2004;25:1345–57.

10. Lu D, Wu Y, Wang Y, Ren F, Wang D, Su F, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell. 2012;21:92–104.

11. Jung HM, Choi SJ, Kim JK. Expression profiles of SV40-immortalization-associated genes upregulated in various human cancers. J Cell Biochem. 2009;106:703–13.

12. She Y, Liang J, Chen L, Qiu Y, Liu N, Zhao X, et al. CREPT expression correlates with poor prognosis in patients with retropitoneal leiomyosarcoma. Int J Clin Exp Pathol. 2014;7:6596–605.

13. Wang Y, Qiu H, Hu W, Li S, Yu J. RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer. Oncol Rep. 2014;31:1389–95.

14. Ma J, Ren Y, Zhang L, Kong X, Wang T, Shi Y, et al. Knocking-down of CREPT prohibits the progress of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression. PLoS ONE. 2017;12:e0174309.

15. Zheng G, Li W, Zuo B, Guo Z, Xi W, Wei M, et al. High expression of CREPT promotes tumor growth and is correlated with poor prognosis in colorectal cancer. Biochem Biophys Res Commun. 2016;480:436–42.

16. Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, et al. Multiple putative oncogenes at the chromosome 20q amplonic contribute to colorectal adenoma to carcinoma progression. Gut. 2009;58:79–89.

17. Xu L, Li X, Cai M, Chen J, Li X, Wu WK, et al. Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer. Gut. 2016;65:635–46.

18. Ni Z, Olsen JB, Guo X, Zhong G, Ruan ED, Marcon E, et al. Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. Transcription. 2011;2:237–42.

19. Ni Z, Xu C, Guo X, Hunter GO, Kuznetsova OV, Tempel W, et al. RPRD1A and RPRD1B are human RNA polymerase II C-terminal domain scaffolds for Ser5 dephosphorylation. Nat Struct Mol Biol. 2014;21:686–95.

20. Ren F, Wang R, Zhang Y, Liu C, Wang Y, Hu J, et al. Characterization of a monoclonal antibody against CREPT, a novel protein highly expressed in tumors. Monoclon Antib Immuno diag Immunother. 2014;33:401–8.

21. Roig AI, Eskiocak U, Hight SK, Kim SB, Delgado O, Souza RF, et al. Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology. 2010;138:1012–21 e1011–1015.

22. Hecht A, Vleminkx K, Stemmler MP, van Roy F, Kelmier R. The p300/CREP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J. 2000;19:1839–50.

23. Sun YN, Kolligs FT, Hottiger MO, Mosavin R, Fearon ER, Nabel GJ. Regulation of beta-catenin transformation by the p300 transcriptional coactivator. Proc Natl Acad Sci USA. 2000;97:12613–8.

24. Levy L, Wei Y, Labatele C, Wu YF, Renard CA, Buendia MA, et al. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol. 2004;24:3404–14.

25. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005;24:3619–31.

26. Mosmann C, Hausmann G, Basler K. beta-Catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009;10:276–U257.

27. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. EMBO J. 2012;31:2714–36.

28. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90:595–606.

29. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001;20:1331–40.

30. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307:269–73.

31. Inuzuka H, Gao D, Finley LW, Yang W, Wan L, Fukushima H, et al. Acetylation-dependent regulation of Skp2 function. Cell. 2012;150:179–93.

32. Takemaru KI, Moon RT. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol. 2000;149:249–54.

33. Wolf D, Redova M, Miska EA, Calvet JP, Kouzarides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem. 2002;277:25562–7.

34. Ge XJ, Jin QH, Zhang F, Yan TT, Zhai QW. PCAF acetylates beta-catenin and improves its stability. Mol Biol Cell. 2009;20:419–27.

35. Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. Chem Rev. 2015;115:2419–52.

36. Chan HM, La Thangue NB. p300/CREP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363–73.

37. Wang S, Dong Y, Zhang Y, Xu L, Yang S, et al. DACT2 is a functional tumor suppressor through inhibiting Wnt/ beta-catenin pathway and associated with poor survival in colon cancer. Oncogene. 2015;34:2575–85.

38. Zhang J, Tsai H, Li X, Wang H, Gao J, Wang K, et al. Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis. Gut. 2015;65:1482–93.

39. Zhang Y, Liu C, Duan X, Ren F, Li S, Jin Z, et al. CREPT/RPRD1B, a recently identified novel protein highly expressed in tumors, enhances the beta-catenin-TCF4 transcriptional activity in response to Wnt signaling. J Biol Chem. 2014;289:22589–99.

40. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 2008;14:226–37.

41. Sun W, Zhang Y, Wong KC, Liu K, Yang Y, Wu B, et al. Increased expression of GATA Zinc Finger Domain Containing 1 via gene amplification promotes liver cancer by directly inducing PRL3. Hepatology. 2017; https://doi.org/10.1002/hep.29750.